BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 33650652)

  • 1. HIPK2 is a potential predictive marker of a favorable response for adjuvant chemotherapy in stage II colorectal cancer.
    Verdina A; Di Segni M; Amoreo CA; Sperduti I; Buglioni S; Mottolese M; Di Rocco G; Soddu S
    Oncol Rep; 2021 Mar; 45(3):899-910. PubMed ID: 33650652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Verbascoside promotes apoptosis by regulating HIPK2-p53 signaling in human colorectal cancer.
    Zhou L; Feng Y; Jin Y; Liu X; Sui H; Chai N; Chen X; Liu N; Ji Q; Wang Y; Li Q
    BMC Cancer; 2014 Oct; 14():747. PubMed ID: 25282590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactivating p53 and Inducing Tumor Apoptosis (RITA) Enhances the Response of RITA-Sensitive Colorectal Cancer Cells to Chemotherapeutic Agents 5-Fluorouracil and Oxaliplatin.
    Wiegering A; Matthes N; Mühling B; Koospal M; Quenzer A; Peter S; Germer CT; Linnebacher M; Otto C
    Neoplasia; 2017 Apr; 19(4):301-309. PubMed ID: 28284059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear factor erythroid 2 (NF-E2) p45-related factor 2 interferes with homeodomain-interacting protein kinase 2/p53 activity to impair solid tumors chemosensitivity.
    D'Orazi G; Garufi A; Cirone M
    IUBMB Life; 2020 Aug; 72(8):1634-1639. PubMed ID: 32593231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulators of the Nrf2 Signaling Pathway Enhance the Cytotoxic Effect of Standard Chemotherapeutic Drugs on Organoids of Metastatic Colorectal Cancer.
    Razumovskaya AV; Silkina MO; Nikulin SV; Tonevitsky AG; Alekseev BY
    Bull Exp Biol Med; 2024 Mar; 176(5):703-708. PubMed ID: 38724815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysosomal acid phosphatase 2 is an unfavorable prognostic factor but is associated with better survival in stage II colorectal cancer patients receiving chemotherapy.
    Lee YC; Su CY; Lin YF; Lin CM; Fang CY; Lin YK; Hsiao M; Chen CL
    Oncotarget; 2017 Feb; 8(7):12120-12132. PubMed ID: 28076332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of colorectal cancer patients with tumors carrying the TP53 mutation on the codon 72 proline allele that benefited most from 5-fluorouracil (5-FU) based postoperative chemotherapy.
    Godai TI; Suda T; Sugano N; Tsuchida K; Shiozawa M; Sekiguchi H; Sekiyama A; Yoshihara M; Matsukuma S; Sakuma Y; Tsuchiya E; Kameda Y; Akaike M; Miyagi Y
    BMC Cancer; 2009 Dec; 9():420. PubMed ID: 19954513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer.
    Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X
    Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crosstalk between NRF2 and HIPK2 shapes cytoprotective responses.
    Torrente L; Sanchez C; Moreno R; Chowdhry S; Cabello P; Isono K; Koseki H; Honda T; Hayes JD; Dinkova-Kostova AT; de la Vega L
    Oncogene; 2017 Nov; 36(44):6204-6212. PubMed ID: 28692050
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Li AJ; Li HG; Tang EJ; Wu W; Chen Y; Jiang HH; Lin MB; Yin L
    World J Gastroenterol; 2018 Feb; 24(5):631-640. PubMed ID: 29434452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637.
    Zhang Y; Li C; Liu X; Wang Y; Zhao R; Yang Y; Zheng X; Zhang Y; Zhang X
    EBioMedicine; 2019 Oct; 48():277-288. PubMed ID: 31631038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a protein signature to enable clinical positioning of IAP inhibitors in colorectal cancer.
    McCann C; Matveeva A; McAllister K; Van Schaeybroeck S; Sessler T; Fichtner M; Carberry S; Rehm M; Prehn JHM; Longley DB
    FEBS J; 2021 Sep; 288(18):5374-5388. PubMed ID: 33660894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling.
    Petty RD; Samuel LM; Murray GI; MacDonald G; O'Kelly T; Loudon M; Binnie N; Aly E; McKinlay A; Wang W; Gilbert F; Semple S; Collie-Duguid ES
    BMC Cancer; 2009 Dec; 9():434. PubMed ID: 20003335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIPK2 phosphorylates ΔNp63α and promotes its degradation in response to DNA damage.
    Lazzari C; Prodosmo A; Siepi F; Rinaldo C; Galli F; Gentileschi M; Bartolazzi A; Costanzo A; Sacchi A; Guerrini L; Soddu S
    Oncogene; 2011 Dec; 30(48):4802-13. PubMed ID: 21602882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quinacrine-Mediated Inhibition of Nrf2 Reverses Hypoxia-Induced 5-Fluorouracil Resistance in Colorectal Cancer.
    Kim HG; Kim CW; Lee DH; Lee JS; Oh ET; Park HJ
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31491980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PKM2 Subcellular Localization Is Involved in Oxaliplatin Resistance Acquisition in HT29 Human Colorectal Cancer Cell Lines.
    Ginés A; Bystrup S; Ruiz de Porras V; Guardia C; Musulén E; Martínez-Cardús A; Manzano JL; Layos L; Abad A; Martínez-Balibrea E
    PLoS One; 2015; 10(5):e0123830. PubMed ID: 25955657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DJ‑1 is a new prognostic marker and predicts chemotherapy efficacy in colorectal cancer.
    Wang W; Wang H; Xiang L; Ni T; Jin F; Deng J; Zhang Y; Shintaro I; Zhou Y; Liu Y
    Oncol Rep; 2020 Jul; 44(1):77-90. PubMed ID: 32627002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy.
    Clausse V; Goloudina AR; Uyanik B; Kochetkova EY; Richaud S; Fedorova OA; Hammann A; Bardou M; Barlev NA; Garrido C; Demidov ON
    Cell Death Dis; 2016 Apr; 7(4):e2195. PubMed ID: 27077811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.